Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy

EMBO Molecular Medicine

Volumn 6, Issue 12, 2014, Pages 1561-1576

  Ebos, John M L ^a   Mastri, Michalis ^a   Lee, Christina R ^b   Tracz, Amanda ^a   Hudson, John M ^b   Attwood, Kristopher ^a   Cruz Munoz, William R ^b   Jedeszko, Christopher ^b   Burns, Peter ^b,c   Kerbel, Robert S ^b,c  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b Sunnybrook Health Sciences Centre   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antibodies; Neoadjuvant; Surgery; Tyrosine kinase inhibitors; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; AXITINIB; B 20; COMBRETASTATIN A1 PHOSPHATE; CRIZOTINIB; CYCLOPHOSPHAMIDE; MONOCLONAL ANTIBODY DC101; PEGDINETANIB; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; UFT; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC THERAPY; ARTICLE; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN CELL; KIDNEY METASTASIS; MELANOMA METASTASIS; METASTASIS; METRONOMIC DRUG ADMINISTRATION; MOUSE; NONHUMAN; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIMARY TUMOR; SIGNAL TRANSDUCTION; SURVIVAL RATE; TREATMENT DURATION; TUMOR XENOGRAFT; ADJUVANT THERAPY; ANIMAL; ANTAGONISTS AND INHIBITORS; GENETICS; METABOLISM; NEOPLASM METASTASIS; NEOPLASMS; PATHOLOGY; SCID MOUSE; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANIMALS; HUMANS; INDOLES; MICE; MICE, SCID; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; NEOPLASMS; PYRROLES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84918578552     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.15252/emmm.201403989     Document Type: Article

References (50)

1. Abel EJ, Culp SH, Tannir NM, Tamboli P, Matin SF, Wood CG (2011) Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib. Eur Urol 60: 1273-1279
2. Bear HD, Tang G, Rastogi P, Geyer CE Jr, Robidoux A, Atkins JN, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L et al (2012) Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 366: 310-320
3. Bex A, Blank C, Meinhardt W, van Tinteren H, Horenblas S, Haanen J (2011) A phase II study of presurgical sunitinib in patients with metastatic clear-cell renal carcinoma and the primary tumor in situ. Urology 78: 832-837
4. Bex A, Haanen J (2014) Do targeted agents offer clinical benefit as presurgical therapy? World J Urol 32: 3-8
5. Bjarnason GA, Naveen BS, Knox JJ, Kollmannsberger M, Reaume N, zalewski P, ZMacfarlane RJ, MacKean MJ, Hotte SJ, Yick D et al (2013) A phase II multicenter study of the efficacy and safety of sunitinib given on an individualized schedule as first-line therapy for metastatic renal cell cancer. ASCO Annual Meeting #TPS4594
6. Blagoev KB, Wilkerson J, Stein WD, Motzer RJ, Bates SE, Fojo AT (2013) Sunitinib does not accelerate tumor growth in patients with metastatic renal cell carcinoma. Cell Rep 3: 277-281
7. Bruix JTT, Mazzaferro V, Chau G, Yang J, Kudo M, Cai J, Poon RT, Han K, Tak W, Lee HC et al (2014) STORM: A phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC). ASCO Annual Meeting #4006
8. Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, Steger GG, Suter TM, Toi M, Parmar M et al (2013) Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol 14: 933-942
9. Chung AS, Kowanetz M, Wu X, Zhuang G, Ngu H, Finkle D, Komuves L, Peale F, Ferrara N (2012) Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors. J Pathol 227: 404-416
10. Cooke VG, LeBleu VS, Keskin D, Khan Z, O'Connell JT, Teng Y, Duncan MB, Xie L, Maeda G, Vong S et al (2012) Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell 21: 66-81
11. Cruz-Munoz W, Man S, Xu P, Kerbel RS (2008) Development of a preclinical model of spontaneous human melanoma central nervous system metastasis. Cancer Res 68: 4500-4505
12. Cruz-Munoz W, Man S, Kerbel RS (2009) Effective treatment of advanced human melanoma metastasis in immunodeficient mice using combination metronomic chemotherapy regimens. Clin Cancer Res 15: 4867-4874
13. Ebos JM, Kerbel RS (2011) Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 8: 210-221
14. Ebos JM, Lee CR, Bogdanovic E, Alami J, Van Slyke P, Francia G, Xu P, Mutsaers AJ, Dumont DJ, Kerbel RS (2008) Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Cancer Res 68: 521-529
15. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15: 232-239
16. Ebos JM, Pili R (2012) Mind the gap: potential for rebounds during antiangiogenic treatment breaks. Clin Cancer Res 18: 3719-3721
17. Francia G, Cruz-Munoz W, Man S, Xu P, Kerbel RS (2011) Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat Rev Cancer 11: 135-141
18. Fumagalli D, Bedard PL, Nahleh Z, Michiels S, Sotiriou C, Loi S, Sparano JA, Ellis M, Hylton N, Zujewski JA et al (2012) A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. Lancet Oncol 13: e240-e248
19. de Gramont A, Van CE, Schmoll HJ, Tabernero J, Clarke S, Moore MJ, Cunningham D, Cartwright TH, Hecht JR, Rivera F et al (2012) Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol 13: 1225-1233
20. Griffioen AW, Mans LA, de Graaf AM, Nowak-Sliwinska P, de Hoog CL, de Jong TA, Vyth-Dreese FA, van Beijnum JR, Bex A, Jonasch E (2012) Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients. Clin Cancer Res 18: 3961-3971
21. Guerin E, Man S, Xu P, Kerbel RS (2013) A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs. Cancer Res 73: 2743-2748
22. Jayson GC, Hicklin DJ, Ellis LM (2012) Antiangiogenic therapy-evolving view based on clinical trial results. Nat Rev Clin Oncol 9: 297-303
23. de John K (2012) Speeding discoveries with neoadjuvant studies. Cancer Discov 2: 294
24. Khattak MA, Edmonds K, Khabra K, Sohaib A, Pennert K, Pickering L, Gore M, Larkin J (2012) Interim results of a phase II study of sunitinib and low dose metronomic cyclophosphamide in advanced renal cell cancer. ESMO Annual Meeting #827P
25. Kroon BK, de Bruijn R, Prevoo W, Horenblas S, Powles T, Bex A (2013) Probability of downsizing primary tumors of renal cell carcinoma by targeted therapies is related to size at presentation. Urology 81: 111-115
26. Miles D, Harbeck N, Escudier B, Hurwitz H, Saltz L, Van Cutsem E, Cassidy J, Mueller B, Sirzen F (2010) Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol 29: 83-88
27. von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R et al (2012a) Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 366: 299-309
28. von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J et al (2012b) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30: 1796-1804
29. Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, Edenfield WJ, Wilding G, Agarwal N, Thompson JA, Cella D et al (2012) Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol 30: 1371-1377
30. Mountzios G, Pentheroudakis G, Carmeliet P (2014) Bevacizumab and micrometastases: revisiting the preclinical and clinical rollercoaster. Pharmacol Ther 141: 117-124
31. Munoz R, Man S, Shaked Y, Lee C, Wong J, Francia G, Kerbel RS (2006) Highly efficacious non-toxic treatment for advanced metastatic breast cancer using combination UFT-cyclophosphamide metronomic chemotherapy. Cancer Res 66: 3386-3391
32. Navid F, Baker SD, McCarville MB, Stewart CF, Billups CA, Wu J, Davidoff AM, Spunt SL, Furman WL, McGregor LM et al (2013) Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors. Clin Cancer Res 19: 236-246
33. Padera TP, Kuo AH, Hoshida T, Liao S, Lobo J, Kozak KR, Fukumura D, Jain RK (2008) Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib. Mol Cancer Ther 7: 2272-2279
34. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15: 220-231
35. Palmieri D, Chambers AF, Felding-Habermann B, Huang S, Steeg PS (2007) The biology of metastasis to a sanctuary site. Clin Cancer Res 13: 1656-1662
36. Pili R, adelaiye R, Miles KM, Ciamporcero E, Sotomayor P, Bjarnason GA (2013) Overcoming sunitinib-induced resistance by dose escalation in renal cell carcinoma: evidence in animal models and patients. ASCO Annual Meeting #4582
37. Schott AF, Hayes DF (2012) Defining the benefits of neoadjuvant chemotherapy for breast cancer. J Clin Oncol 30: 1747-1749
38. Schrader AJ, Steffens S, Schnoeller TJ, Schrader M, Kuczyk MA (2012) Neoadjuvant therapy of renal cell carcinoma: a novel treatment option in the era of targeted therapy? Int J Urol 19: 903-907
39. Sennino B, Ishiguro-Oonuma T, Wei Y, Naylor RM, Williamson CW, Bhagwandin V, Tabruyn SP, You WK, Chapman HA, Christensen JG et al (2012) Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov 2: 270-287
40. Silberstein JL, Millard F, Mehrazin R, Kopp R, Bazzi W, Diblasio CJ, Patterson AL, Downs TM, Yunus F, Kane CJ et al (2010) Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery. BJU Int 109: 1270-1276
41. Singh M, Ferrara N (2012) Modeling and predicting clinical efficacy for drugs targeting the tumor milieu. Nat Biotechnol 30: 648-657
42. de Souza BM, Chaves KB, Chammas R, Schor N, Bellini MH (2012) Endostatin neoadjuvant gene therapy extends survival in an orthotopic metastatic mouse model of renal cell carcinoma. Biomed Pharmacother 66: 237-241
43. Starlinger P, Alidzanovic L, Schauer D, Maier T, Nemeth C, Perisanidis B, Tamandl D, Gruenberger B, Gruenberger T, Brostjan C (2012) Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation. Br J Cancer 107: 961-966
44. Steeg PS, Anderson RL, Menash B, Chambers AF, Eccles SA, Hunter K, Itoh K, Kang Y, Matrisian LM, Sleeman JP et al (2009) Preclinical drug development must consider the impact on metastasis. Clin Cancer Res 15: 4529-4530
45. Tanvetyanon T, Clark JI, Campbell SC, Lo SS (2005) Neoadjuvant therapy: an emerging concept in oncology. South Med J 98: 338-344
46. Tracz A, Mastri M, Lee CR, Pili R, Ebos JM (2014) Modeling spontaneous metastatic renal cell carcinoma (mRCC) in mice following nephrectomy. J Vis Exp e51485
47. Van Cutsem E, Labianca R, Bodoky G, Barone C, Aranda E, Nordlinger B, Topham C, Tabernero J, Andre T, Sobrero AF et al (2009) Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 27: 3117-3125
48. van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Bex A, de Gast G, Haanen JB, Boven E (2008) Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin Cancer Res 14: 2431-2436
49. Wang X, Zhang L, Goldberg SN, Bhasin M, Brown V, Alsop DC, Signoretti S, Mier JW, Atkins MB, Bhatt RS (2011) High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma. J Transl Med 9: 220
50. Welti JC, Powles T, Foo S, Gourlaouen M, Preece N, Foster J, Frentzas S, Bird D, Sharpe K, van Weverwijk A et al (2012) Contrasting effects of sunitinib within in vivo models of metastasis. Angiogenesis 15: 623-641